ADVM — Adverum Biotechnologies Income Statement
0.000.00%
Last trade - 00:00- $94.05m
- $67.99m
- $1.00m
Annual income statement for Adverum Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 7.5 | 0 | 3.6 | 1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 118 | 154 | 157 | 133 | 140 |
| Operating Profit | -118 | -146 | -157 | -129 | -139 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -116 | -146 | -154 | -123 | -131 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -118 | -146 | -155 | -122 | -131 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -118 | -146 | -155 | -122 | -131 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -118 | -146 | -155 | -122 | -131 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -13.8 | -14.7 | -15.4 | -12.1 | -6.62 |